• Anixa Biosciences issued a correction to its May 11 release on updated survival observations from its Phase 1 lira-cel ovarian cancer CAR-T trial, without specifying what was changed.
• Corrected release reiterated that several patients lived well beyond an expected median survival of three to four months, including one patient who survived 28 months.
• It also restated preliminary safety observations showing no dose-limiting toxicities in first three dose cohorts, no ICANS or significant CRS, with significant adverse events to date assessed as unrelated to lira-cel.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Anixa Biosciences Inc. published the original content used to generate this news brief on May 11, 2026, and is solely responsible for the information contained therein.